Tolvaptan in patients with autosomal dominant polycystic kidney disease. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, TEMPO 3:4 Trial Investigators (2012) N Engl J Med 367: 2407-18 Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS, TEMPOFormula and 156-05-002 Study Investigators (2011) Clin J Am Soc Nephrol 6: 2499-507 A novel experimental strategy to assess the metabolic effects of selective activation of a G(q)-coupled receptor in hepatocytes in vivo. Li JH, Jain S, McMillin SM, Cui Y, Gautam D, Sakamoto W, Lu H, Jou W, McGuinness OP, Gavrilova O, Wess J (2013) Endocrinology 154: 3539-51 Advocating for mutually beneficial access to shelved compounds. Pulley JM, Jerome RN, Shirey-Rice JK, Zaleski NM, Naylor HM, Pruijssers AJ, Jackson JC, Bernard GR, Holroyd KJ (2018) Future Med Chem 10: 1395-1398
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.